Methods of treating auto-inflammatory syndromes using il-1beta antibodies

Abstract

This invention relates to a novel use of IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1b ligand-IL-1 receptor interaction, IL-1b antibodies or IL-1 receptor antibodies, e.g. IL-1b binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1b binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1b ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.

1 - 22 . (canceled) 
     
     
         23 . A method of treating an auto-inflammatory syndrome in a patient in need thereof, comprising administering to said patient an effective amount of an IL-1beta binding antibody comprising an antigen binding site comprising:
 a) at least one immunoglobulin heavy chain variable domain (V H ) which comprises in sequence hypervariable regions CDR1, CDR2 and CDR3, the CDR1 comprising the amino acid sequence set forth as SEQ ID NO: 3, the CDR2 comprising the amino acid sequence set forth as SEQ ID NO: 4, and the CDR3 comprising the amino acid sequence set forth as SEQ ID NO: 5; and   b) at least one immunoglobulin heavy chain variable domain (V L ) which comprises in sequence hypervariable regions CDR1′, CDR2′ and CDR3′, the CDR1′ comprising the amino acid sequence set forth as SEQ ID NO: 6, the CDR2′ comprising the amino acid sequence set forth as SEQ ID NO: 7, the CDR3′ comprising the amino acid sequence set forth as SEQ ID NO: 8,   
       wherein the antibody is parenterally administered at a dose between 0.1-50 mg of the antibody per kg body weight of the patient. 
     
     
         24 . The method according to  claim 23 , wherein the IL-1beta binding antibody comprises a V H  comprising the amino acid sequence set forth as SEQ ID NO:1 and a V L  comprising the amino acid sequence set forth as SEQ ID NO:2. 
     
     
         25 . The method according to  claim 23  wherein the IL-1beta binding antibody is administered once every week or less frequently. 
     
     
         26 . The method according to  claim 23 , wherein the IL-1beta binding antibody is administered subcutaneously. 
     
     
         27 . The method according to  claim 23 , wherein the IL-1beta binding antibody is administered intraveneously. 
     
     
         28 . The method according to  claim 23 , wherein the IL-1beta binding antibody is administered at a dose between 1-10 mg of the antibody per kg body weight of the patient. 
     
     
         29 . The method according to  claim 23 , wherein the IL-1beta binding antibody is administered once every month or less frequently. 
     
     
         30 . The method according to  claim 23 , wherein the IL-1beta binding antibody is administered once every week or less frequently. 
     
     
         31 . The method according to  claim 23 , wherein the IL-1beta binding antibody is administered once every month. 
     
     
         32 . The method according to  claim 23 , wherein the IL-1beta binding antibody is canakinumab. 
     
     
         33 . The method according to  claim 23 , wherein the auto-inflammatory syndrome is selected from: Muckle-Wells syndromes (MWS), LADA (Latent Autoimmune Diabetes in Adults), familial cold autoinflammmatory syndrome (FCAS), Cryopyrin-associated periodic syndromes (CAPS), neonatal-onset mutlisystem inflammatory syndrome (NOMID), chronic infantile neurological, cutaneous, articular (CINCA) syndrome, familial Mediterranean fever (FMF), and arthritis. 
     
     
         34 . The method according to  claim 23 , wherein the auto-inflammatory syndrome is selected from: juvenile arthritis, juvenile rheumatoid arthritis, and adult rheumatoid arthritis. 
     
     
         35 . The method according to  claim 34 , wherein the juvenile arthritis is systemic onset juvenile idiopathic arthritis (SJIA). 
     
     
         36 . The method according to  claim 34 , wherein the juvenile rheumatoid arthritis is systemic onset juvenile idiopathic rheumatoid arthritis.